53
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          On February 9, 2021, this report was posted online as an MMWR Early Release. As of February 8, 2021, 59.3 million doses of vaccines to prevent coronavirus disease 2019 (COVID-19) had been distributed in the United States, and 31.6 million persons had received at least 1 dose of the COVID-19 vaccine ( 1 ). However, national polls conducted before vaccine distribution began suggested that many persons were hesitant to receive COVID-19 vaccination ( 2 ). To examine perceptions toward COVID-19 vaccine and intentions to be vaccinated, in September and December 2020, CDC conducted household panel surveys among a representative sample of U.S. adults. From September to December, vaccination intent (defined as being absolutely certain or very likely to be vaccinated) increased overall (from 39.4% to 49.1%); the largest increase occurred among adults aged ≥65 years. If defined as being absolutely certain, very likely, or somewhat likely to be vaccinated, vaccination intent increased overall from September (61.9%) to December (68.0%). Vaccination nonintent (defined as not intending to receive a COVID-19 vaccination) decreased among all adults (from 38.1% to 32.1%) and among most sociodemographic groups. Younger adults, women, non-Hispanic Black (Black) persons, adults living in nonmetropolitan areas, and adults with lower educational attainment, with lower income, and without health insurance were most likely to report lack of intent to receive COVID-19 vaccine. Intent to receive COVID-19 vaccine increased among adults aged ≥65 years by 17.1 percentage points (from 49.1% to 66.2%), among essential workers by 8.8 points (from 37.1% to 45.9%), and among adults aged 18–64 years with underlying medical conditions by 5.3 points (from 36.5% to 41.8%). Although confidence in COVID-19 vaccines increased during September–December 2020 in the United States, additional efforts to tailor messages and implement strategies to further increase the public’s confidence, overall and within specific subpopulations, are needed. Ensuring high and equitable vaccination coverage across all populations is important to prevent the spread of COVID-19 and mitigate the impact of the pandemic. The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for COVID-19 vaccine allocation, with initial limited supplies of vaccines recommended for health care personnel and residents of long-term care facilities (phase 1a); frontline essential workers and persons aged ≥75 years (phase 1b); and persons aged 65–74 years, persons aged 16–64 years at high risk for severe COVID-19 illness because of underlying medical conditions,* and other workers in essential and critical infrastructure sectors † not included in phases 1a and 1b (phase 1c) ( 3 , 4 ). Vaccinating a large proportion of persons in the United States against COVID-19 is critical for preventing SARS-CoV-2–associated morbidity and mortality and helping bring an end to the global pandemic. During September 3–October 1, CDC conducted a probability-based Internet panel survey (IPSOS KnowledgePanel) § of a nationally representative sample of 3,541 U.S. adult panelists aged ≥18 years to assess intent to receive a COVID-19 vaccine and perceptions about the vaccine ( 5 ). During December 18–20, CDC sponsored questions on two probability-based household panel omnibus surveys (IPSOS KnowledgePanel ¶ and NORC Amerispeak**) administered to 2,033 panelists (approximately 1,000 panelists each) to reassess COVID-19 vaccination intent and related perceptions. †† This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. §§ The same questions about COVID-19 vaccine intentions, perceptions, and reasons for not receiving a COVID-19 vaccine were asked in the September and December surveys. However, most respondents were different for each survey; only 123 panelists (3.5%) completed both the September and December IPSOS survey. Intent was assessed by response to the following question: “If a vaccine against COVID-19 were available today at no cost, how likely would you be to get it?” Response options were “absolutely certain,” “very likely,” “somewhat likely,” and “not likely.” Respondents who answered “absolutely certain” or “very likely” to receive a COVID-19 vaccination were defined as intending to be vaccinated, and respondents who answered “not likely” were defined as not intending to be vaccinated. Vaccination intentions and related perceptions were stratified by the following three mutually exclusive groups representing the ACIP priorities for initial doses of COVID-19 vaccine after health care providers and long-term care residents: 1) essential workers, ¶¶ 2) adults aged 18–64 years with underlying medical conditions, and 3) adults aged ≥65 years.*** Sample size for the December surveys was not large enough to stratify the analysis by age group (65–74 years versus ≥75 years) or essential worker subgroups (health care personnel, other frontline essential workers, and other non-frontline essential workers). Analyses were also conducted to provide estimates among all adults and among adults not included in the initial ACIP priority groups (aged 18–64 years with no underlying medical conditions and who were not essential workers). Responses to questions on intent, perceptions, and reasons for not getting vaccinated were examined by sociodemographic characteristics and priority groups for the September and December surveys. Because of similar sampling methods and characteristics of respondents, the averages of the estimates from the two December surveys were calculated, and the difference between the September survey and the average of the December surveys was determined using t-tests. All surveys were weighted to ensure representativeness of the U.S. population, and all analyses were conducted using SAS-callable SUDAAN (version 11.0; RTI International). From September to December, the proportion of adults reporting intent to receive COVID-19 vaccine as absolutely certain or very likely increased significantly by 9.7 percentage points (from 39.4% to 49.1%), and the proportion reporting nonintent decreased by 6.0 percentage points (from 38.1% to 32.1%) (Table 1). Among priority groups, intent increased by 17.1 percentage points among adults aged ≥65 years (from 49.1% to 66.2%), by 8.8 percentage points among essential workers (from 37.1% to 45.9%), and by 5.3 percentage points among adults aged 18–64 years with underlying medical conditions (from 36.5% to 41.8%) (Supplementary Figure, https://stacks.cdc.gov/view/cdc/101583). TABLE 1 COVID-19 vaccination intent among surveyed adults, by vaccination priority group — United States, September and December 2020 Characteristic Weighted % (95% CI) IPSOS, Sep 2020*
(n = 3,541) IPSOS, Dec 2020†
(n = 1,005) NORC, Dec 2020§
(n = 1,028) Average of Dec IPSOS† and NORC§ estimates
(n = 2,033) Difference between Dec and Sep estimates¶ All adults Intent to get COVID-19 vaccine Absolutely certain/Very likely** 39.4 (37.7 to 41.2) 50.3 (46.9 to 53.6) 47.8 (42.7 to 52.8) 49.1 (46.0 to 52.1) 9.7 (6.2 to 13.2) Somewhat likely 22.5 (21.0 to 24.0) 16.8 (14.2 to 19.4) 21.0 (17.4 to 24.8) 18.9 (16.4 to 21.4) −3.6 (−6.5 to −0.7) Not likely 38.1 (36.4 to 39.8) 33.0 (29.7 to 36.2) 31.2 (26.5 to 35.8) 32.1 (29.6 to 34.6) −6.0 (−9.0 to −3.0) Essential workers Intent to get COVID-19 vaccine Absolutely certain/Very likely** 37.1 (34.2 to 40.0) 49.0 (42.9 to 55.1) 42.8 (34.9 to 50.6) 45.9 (40.9 to 50.9) 8.8 (3.0 to 14.6) Somewhat likely 22.8 (20.2 to 25.3) 14.4 (9.9 to 19.1) 23.0 (16.6 to 29.6) 18.7 (14.0 to 23.4) −4.1 (−9.4 to 1.2) Not likely 40.2 (37.3 to 43.2) 36.6 (30.7 to 42.3) 34.2 (25.8 to 42.6) 35.4 (30.8 to 40.0) −4.8 (−10.3 to 0.7) Adults aged ≥65 yrs Intent to get COVID-19 vaccine Absolutely certain/Very likely** 49.1 (45.6 to 52.6) 66.5 (60.0 to 73.0) 65.8 (59.0 to 72.6) 66.2 (61.5 to 70.8) 17.1 (11.3 to 22.9) Somewhat likely 21.1 (18.3 to 23.9) 12.8 (8.4 to 17.2) 17.4 (12.0 to 22.9) 15.1 (11.6 to 18.6) −6.0 (−10.5 to −1.5) Not likely 29.8 (26.6 to 33.0) 20.6 (14.9 to 26.4) 16.8 (10.2 to 23.3) 18.7 (14.3 to 23.0) −11.1 (−16.5 to −5.7) Adults aged 18–64 yrs with underlying medical conditions Intent to get COVID-19 vaccine Absolutely certain/Very likely** 36.5 (33.4 to 39.6) 44.8 (38.0 to 51.5) 38.8 (32.6 to 45.1) 41.8 (37.2 to 46.4) 5.3 (−0.2 to 10.8) Somewhat likely 23.0 (20.3 to 25.7) 19.2 (13.3 to 25.0) 20.6 (14.7 to 26.6) 19.9 (15.7 to 24.1) −3.1 (−8.1 to 1.9) Not likely 40.4 (37.3 to 43.7) 36.0 (29.4 to 42.8) 40.5 (34.5 to 46.5) 38.3 (33.8 to 42.8) −2.1 (−7.6 to 3.4) Adults aged 18–64 yrs without underlying medical conditions and nonessential workers Intent to get COVID-19 vaccine Absolutely certain/Very likely** 38.0 (34.5 to 41.4) 46.3 (40.5 to 52.1) 48.7 (40.0 to 57.4) 47.5 (42.3 to 52.7) 9.5 (3.3 to 15.7) Somewhat likely 22.4 (19.4 to 25.2) 18.4 (13.8 to 23.1) 22.2 (13.2 to 31.3) 20.3 (15.2 to 25.4) −2.1 (−8.0 to 3.8) Not likely 39.8 (36.4 to 43.1) 35.2 (29.5 to 41.0) 29.0 (20.9 to 37.2) 32.2 (27.2 to 37.1) −7.6 (−13.6 to −1.6) Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019. * IPSOS KnowledgePanel Survey, fielded September 3–October 1. † IPSOS KnowledgePanel Omnibus Survey, fielded December 18–20. § NORC AmeriSpeak Omnibus Survey, fielded December 18–20. ¶ CIs for differences that exclude zero are statistically significant. ** Might include some persons who already received the COVID-19 vaccine. Vaccination nonintent differed by sociodemographic characteristics and decreased across most socioeconomic groups from September to December (Table 2). For example, nonintent decreased by 10.3 percentage points among adults aged 50–64 years and by 11.1 percentage points among adults aged ≥65 years. Although nonintent was higher among women, nonintent among both women and men decreased by 6.0 percentage points between September and December. Nonintent was highest among Black persons in September (56.1%) and December (46.5%) compared with other racial/ethnic groups, with the difference between months (−9.6) not statistically significant. Nonintent was higher among adults with lower educational attainment and lower income but decreased across most education and income categories: among adults with a high school diploma or less, nonintent decreased 7.9 percentage points, and in households with annual incomes of $35,000–$49,999, nonintent decreased by 10.8 percentage points. Vaccination nonintent also decreased in metropolitan statistical areas ††† by 6.7 percentage points and among adults in all regions of the United States, except the Northeast, including decreases of 8.3 percentage points in the South, 6.8 in the Midwest, and 6.8 in the West. In December, nonintent was highest among persons without health insurance (44.5%), compared with those who had private health insurance (30.7%) and public health insurance (29.6%), and was similar in September and December. TABLE 2 Prevalence of intent not to receive COVID-19 vaccine, by selected characteristics — United States, September and December 2020 Characteristic Weighted % (95% CI) IPSOS, Sep 2020*
(n = 3,541) Average of Dec IPSOS† and NORC§ estimates
(n = 2,033) Difference between Dec and Sep estimates ¶ All adults, aged ≥18 yrs Age group, yrs 18–49 (ref) 39.5 (36.9 to 42.0) 37.6 (33.5 to 41.7) −1.9 (−6.7 to 3.0) 50–64 42.0 (38.9 to 45.2) 31.7 (26.6 to 36.8) −10.3 (−16.3 to −4.3) ≥65 29.8** (26.6 to 33.0) 18.7** (14.3 to 23.1) −11.1 (−16.5 to −5.7) Sex Male 33.8** (31.4 to 36.2) 27.8** (24.7 to 30.9) −6.0 (−9.9 to −2.1) Female (ref) 42.1 (39.7 to 44.6) 36.0 (31.4 to 40.6) −6.1 (−11.3 to −0.9) Race/Ethnicity White, non-Hispanic (ref) 35.9 (33.8 to 38.1) 30.3 (27.4 to 33.2) −5.6 (−9.2 to −2.0) Black, non-Hispanic 56.1** (51.4 to 60.8) 46.5** (36.8 to 56.2) −9.6 (−20.4 to 1.2) Hispanic 36.4 (31.8 to 41.0) 32.4 (26.2 to 38.6) −4.0 (−11.7 to 3.7) Other/Multiple races, non-Hispanic 32.1 (27.4 to 36.8) 24.4 (17.0 to 31.9) −7.7 (−16.5 to 1.1) Educational status High school or less (ref) 47.0 (44.0 to 50.0) 39.1 (34.0 to 44.2) −7.9 (−13.8 to −2.0) Some college or college graduate 35.8** (33.4 to 38.2) 30.9** (27.9 to 33.8) −4.9 (−8.7 to −1.1) Above college graduate 23.8** (20.3 to 27.3) 15.7** (11.1 to 20.4) −8.1 (−13.9 to −2.3) Employment status Employed (ref) 38.6 (36.5 to 40.8) 32.3 (29.2 to 35.4) −6.3 (−10.1 to −2.5) Not employed/Not in workforce 36.6 (33.8 to 39.5) 31.5 (27.1 to 35.9) −5.1 (−10.3 to 0.1) Annual household income, $ <35,000 (ref) 44.0 (40.2 to 47.7) 38.3 (32.4– to 44.1) −5.7 (−12.6 to 1.2) 35,000–49,999 45.1 (40.0 to 50.2) 34.3 (26.7 to 41.9) −10.8 (−20.0 to −1.6) 50,000–74,999 39.8 (35.5 to 44.2) 39.7 (34.5 to 44.9) −0.1 (−6.9 to 6.7) ≥75,000 33.5** (31.1 to 35.9) 23.9** (20.6 to 27.3) −9.6 (−13.7 to −5.5) Region Northeast (ref) 35.2 (31.3 to 39.1) 35.5 (29.6 to 41.4) 0.3 (−6.8 to 7.4) Midwest 36.7 (33.0 to 40.4) 30.3 (25.3 to 35.3) −6.4 (−12.6 to −0.2) South 41.1** (38.3 to 44.0) 32.8 (27.5 to 38.2) −8.3 (−14.4 to −2.2) West 36.7 (33.2 to 40.1) 29.9 (24.4 to 35.4) −6.8 (−13.3 to −0.3) Health insurance status Private health insurance (ref) 37.8 (35.6 to 40.0) 30.7 (27.2 to 34.3) −7.1 (−11.3 to −2.9) Public health insurance 35.3 (32.4 to 38.2) 29.6 (25.1 to 34.2) −5.7 (−11.1 to −0.3) No health insurance 48.7** (42.1 to 55.2) 44.5** (33.4 to 55.5) −4.2 (−17.0–8.6) MSA status Metro (ref) 36.9 (35.1 to 38.7) 30.2 (27.0 to 33.4) −6.7 (−10.4 to −3.0) Nonmetro 46.2** (41.3 to 51.1) 39.6** (33.5 to 45.7) −6.6 (−14.4 to 1.2) 2020–21 influenza vaccination status Received influenza vaccination/Absolutely certain (ref) 23.3 (21.2 to 25.5) 14.7 (12.0 to 17.3) −8.6 (−12.0 to −5.2) Very likely/Somewhat likely 30.3** (27.0 to 33.6) 20.6 (14.6 to 26.5) −9.7 (−16.5 to −2.9) Not likely 67.0** (63.9 to 70.2) 68.3** (63.7 to 72.9) 1.3 (−4.3–6.9) Concern about COVID-19 illness for self Very/Somewhat concerned (ref) 27.6 (25.6 to 29.8) 18.8 (15.9 to 21.7) −8.8 (−12.4 to −5.2) Slightly/Not concerned 50.1** (47.4 to 52.7) 51.3** (47.2 to 55.3) 1.2 (−3.6 to 6.0) Concern about side effects of vaccine for self Very/Somewhat concerned (ref) 43.7 (41.5 to 46.0) 40.5 (36.7 to 44.2) −3.2 (−7.6 to 1.2) Slightly/Not concerned 28.9** (26.3 to 31.6) 21.5** (18.4 to 24.6) −7.4 (−11.5 to −3.3) Trust governmental approval process to ensure the COVID-19 vaccine is safe for the public Fully/Mostly trust (ref) 9.5 (7.9 to 11.2) 7.7 (5.6 to 9.9) −1.8 (−4.5 to 0.9) Somewhat trust/Do not trust 56.7** (54.4 to 58.9) 54.3 (50.4 to 58.2) −2.4 (−6.9 to 2.1) Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019; MSA = metropolitan statistical area; ref = reference category. * IPSOS KnowledgePanel Survey, fielded September 3–October 1. † IPSOS KnowledgePanel Omnibus Survey, fielded December 18–20. § NORC AmeriSpeak Omnibus Survey, fielded December 18–20. ¶ CIs for differences that exclude zero are statistically significant. ** p<0.05 compared with respective reference category for each variable (by t-test). Among adults in the December surveys who did not intend to get vaccinated, the main reasons most frequently cited were concerns about side effects and safety of the COVID-19 vaccine (29.8%), planning to wait to see if the vaccine is safe and consider receiving it later (14.5%), lack of trust in the government (12.5%), and concern that COVID-19 vaccines were developed too quickly (10.4%) (Table 3). A larger percentage of the December survey participants than September participants reported safety concerns as a main reason (29.8% versus 23.4%), and a smaller percentage reported concern that vaccines were developed too quickly (10.4% versus 21.6%). TABLE 3 Main reasons for not intending to get COVID-19 vaccine,* United States, September and December 2020 Main reasons Weighted % (95% CI) IPSOS, Sep 2020†
(n = 3,541) Average of Dec IPSOS§ and NORC¶ estimates
(n = 2,033) Difference between Dec and Sep estimates** Concern about the side effects and safety of the vaccine 23.4 (20.9 to 25.9) 29.8 (26.2 to 33.4) 6.4 (2.0 to 10.8) Concern that the vaccine is being developed too quickly 21.6 (19.3 to 24.1) 10.4 (7.6 to 13.2) −11.2 (−14.9 to −7.5) Plan to wait and see if it is safe and may get it later 18.0 (15.7 to 20.2) 14.5 (11.1 to 17.9) −3.5 (−7.6 to 0.6) Don’t trust the government 9.8 (8.0 to 11.6) 12.5 (9.0 to 15.9) 2.7 (−1.2 to 6.6) Plan to use masks/other precautions instead 3.4 (2.4 to 4.4) 3.7 (1.4 to 6.0) 0.3 (−2.2 to 2.8) Don’t like vaccines 3.2 (2.2 to 4.1) 5.4 (3.0 to 7.9) 2.2 (−0.4 to 4.8) Not a member of any group that is at high risk for COVID-19 2.8 (1.9 to 3.8) 3.5 (1.8 to 5.1) 0.7 (−1.2 to 2.6) COVID-19 is not a serious illness 2.6 (1.6 to 3.6) 1.9 (0.8 to 3.0) −0.7 (−2.2 to 0.8) The vaccine will not work 2.4 (1.5 to 3.3) 0.0 (—) −2.4 (−3.3 to −1.5) The vaccine could give me COVID-19 2.4 (1.5 to 3.3) 2.3 (0.0 to 5.4) −0.1 (−2.9 to 2.7) Had COVID-19 and should be immune 1.0 (0.4 to 1.6) 2.2 (1.0 to 3.5) 1.2 (−0.2 to 2.6) Don’t like needles 1.0 (0.5 to 1.6) 3.0 (0.1 to 6.0) 2.0 (−1.0 to 5.0) Doctor has not recommended a COVID-19 vaccine to me 0.8 (0.4 to 1.4) 0.0 (—) −0.8 (−1.3 to −0.3) Didn’t know I needed a vaccine against COVID-19 0.2 (0.0 to 0.5) 0.4 (0.0 to 1.0) 0.2 (−0.4 to 0.8) Concern about the costs associated with the vaccine (such as office visit costs or vaccine administration fees) 0.2 (0.0 to 0.3) 0.2 (0.0 to 0.8) 0.0 (−0.4 to 0.4) Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019. * Among respondents who stated that they are not likely to receive the COVID-19 vaccine. † IPSOS KnowledgePanel Survey, fielded September 3–October 1. § IPSOS KnowledgePanel Omnibus Survey, fielded December 18–20. ¶ NORC AmeriSpeak Omnibus Survey, fielded December 18–20. ** CIs for differences that exclude zero are statistically significant. Discussion From September to December 2020, vaccination intent increased among all adults by approximately 10 percentage points and across all priority groups, with the largest increase in intent to be vaccinated among adults aged ≥65 years; vaccination nonintent decreased among all adults by 6 percentage points and across most sociodemographic groups. However, despite increases in vaccination intent since September ( 5 ), only about half of persons aged 18–64 years surveyed in December reported being very likely to receive COVID-19 vaccination, even among those who were essential workers and persons aged 18–64 years with underlying medical conditions. Younger adults, women, Black persons, adults living in nonmetropolitan areas, and adults with lower educational attainment, with lower income, and without insurance were most likely to report that they did not intend to receive COVID-19 vaccination. Several studies found similar percentages and trends in vaccination intent and low likelihood of receiving a COVID-19 vaccine among groups disproportionately affected by COVID-19, including Black persons and those with lower educational attainment ( 6 , 7 ). Because many of these groups are at increased risk for COVID-19–associated morbidity and mortality ( 8 ), COVID-19 vaccination is important for protecting the health of these populations and reducing health inequities. The findings in this report are subject to at least seven limitations. First, although panel recruitment methodology and data weighting were designed to produce nationally representative results, respondents might not be fully representative of the general U.S. adult population. Second, because the sample of persons surveyed in December was not derived from the sample of persons surveyed in September, longitudinal analysis of changes in perception from the same sample of persons was not possible. Third, small sample sizes prevented separate analyses of some priority groups identified by ACIP, such as health care personnel, frontline and other essential workers, and adults aged 65–74 years and ≥75 years. Fourth, because essential worker status and high-risk medical conditions were self-reported, there might be potential for misclassification. Respondents were also placed into mutually exclusive vaccine priority groups, which could not account for persons who fit within multiple groups (e.g., essential workers aged 18–64 years with underlying medical conditions). Fifth, attitudes and perceptions might change quickly, and these results might not be reflective of current reasons for not intending to receive a COVID-19 vaccine. Sixth, results are national estimates and cannot be generalized to the state or local level. Finally, results might not be comparable to other national polls or surveys because of potential differences in survey methods, sample population, and questions related to vaccination intent. Continuing to promote vaccine confidence by tailoring information to address concerns of individual persons and communities is critical to preventing the spread of COVID-19. These findings suggest a decrease in nonintent over time as well as concerns about vaccine safety among priority populations in the United States and have implications for potential messages and strategies that could boost confidence in COVID-19 vaccines and educate essential workers, minority populations, and the general public about the safety of the vaccine development process, and the known effectiveness and safety of authorized COVID-19 vaccines ( 9 ). Health care providers are known to be a trusted source of information about vaccines for many persons and can use CDC-recommended guidance to have effective conversations with patients about the need for vaccination ( 10 ). Ensuring high and equitable vaccination coverage in all populations is critical to preventing the spread of COVID-19 and bringing an end to the pandemic. Summary What is already known about this topic? National polls conducted before vaccine distribution began suggested that many persons were hesitant to receive COVID-19 vaccination. What is added by this report? From September to December 2020, intent to receive COVID-19 vaccination increased from 39.4% to 49.1% among adults and across all priority groups, and nonintent decreased from 38.1% to 32.1%. Despite decreases in nonintent from September to December, younger adults, women, non-Hispanic Black adults, adults living in nonmetropolitan areas, and adults with less education and income, and without health insurance continue to have the highest estimates of nonintent to receive COVID-19 vaccination. What are the implications for public health practice? Ensuring high and equitable vaccination coverage among all populations, including by addressing reasons for not intending to receive vaccination, is critical to prevent the spread of COVID-19 and bring an end to the pandemic.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Determinants of COVID-19 vaccine acceptance in the US

          Background The COVID-19 pandemic continues to adversely affect the U.S., which leads globally in total cases and deaths. As COVID-19 vaccines are under development, public health officials and policymakers need to create strategic vaccine-acceptance messaging to effectively control the pandemic and prevent thousands of additional deaths. Methods Using an online platform, we surveyed the U.S. adult population in May 2020 to understand risk perceptions about the COVID-19 pandemic, acceptance of a COVID-19 vaccine, and trust in sources of information. These factors were compared across basic demographics. Findings Of the 672 participants surveyed, 450 (67%) said they would accept a COVID-19 vaccine if it is recommended for them. Males (72%) compared to females, older adults (≥55 years; 78%) compared to younger adults, Asians (81%) compared to other racial and ethnic groups, and college and/or graduate degree holders (75%) compared to people with less than a college degree were more likely to accept the vaccine. When comparing reported influenza vaccine uptake to reported acceptance of the COVID-19 vaccine: 1) participants who did not complete high school had a very low influenza vaccine uptake (10%), while 60% of the same group said they would accept the COVID-19 vaccine; 2) unemployed participants reported lower influenza uptake and lower COVID-19 vaccine acceptance when compared to those employed or retired; and, 3) Black Americans reported lower influenza vaccine uptake and lower COVID-19 vaccine acceptance than all other racial groups reported in our study. Lastly, we identified geographic differences with Department of Health and Human Services (DHHS) regions 2 (New York) and 5 (Chicago) reporting less than 50 percent COVID-19 vaccine acceptance. Interpretation Although our study found a 67% acceptance of a COVID-19 vaccine, there were noticeable demographic and geographical disparities in vaccine acceptance. Before a COVID-19 vaccine is introduced to the U.S., public health officials and policymakers must prioritize effective COVID-19 vaccine-acceptance messaging for all Americans, especially those who are most vulnerable.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020

              The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic that has disrupted all sectors of society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization for a candidate vaccine has been filed with the Food and Drug Administration (FDA). However, even if one or more vaccine candidates receive authorization for emergency use, demand for COVID-19 vaccine is expected to exceed supply during the first months of the national vaccination program. The Advisory Committee on Immunization Practices (ACIP) advises CDC on population groups and circumstances for vaccine use. † ACIP convened on December 1, 2020, in advance of the completion of FDA’s review of the Emergency Use Authorization application, to provide interim guidance to federal, state, and local jurisdictions on allocation of initial doses of COVID-19 vaccine. ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and recommended by ACIP, both 1) health care personnel § and 2) residents of long-term care facilities (LTCFs) ¶ be offered vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a**). †† In its deliberations, ACIP considered scientific evidence of SARS-CoV-2 epidemiology, vaccination program implementation, and ethical principles. §§ The interim recommendation might be updated over the coming weeks based on additional safety and efficacy data from phase III clinical trials and conditions of FDA Emergency Use Authorization. Evidence-based information addressing COVID-19 vaccine topics including early allocation has been explicitly and transparently reviewed during seven public ACIP meetings ( 1 ). To inform policy options for ACIP, the COVID-19 Vaccines Work Group, comprising experts in vaccines and ethics, held more than 25 meetings to review data regarding vaccine candidates, COVID-19 surveillance, and modeling, as well as the vaccine allocation literature from published and external expert committee reports. Health care settings in general, and long-term care settings in particular, can be high-risk locations for SARS-CoV-2 exposure and transmission ( 2 – 4 ). Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials. As of December 1, 2020, approximately 245,000 COVID-19 cases and 858 COVID-19-associated deaths had been reported among U.S. health care personnel ( 5 ). Early protection of health care personnel is critical to preserve capacity to care for patients with COVID-19 or other illnesses. LTCF residents are defined as adults who reside in facilities that provide a range of services, including medical and personal care, to persons who are unable to live independently. LTCF residents, because of their age, high rates of underlying medical conditions, and congregate living situation, are at high risk for infection and severe illness from COVID-19. As of November 15, 2020, approximately 500,000 COVID-19 cases and 70,000 associated deaths had been reported among residents of skilled nursing facilities, a subset of LTCFs serving residents with more complex medical needs ( 6 ). With respect to vaccination program implementation, vaccines that require cold and ultracold storage, specialized handling, and large minimum order requirements are most feasibly maintained in centralized vaccination clinics, such as acute health care settings, or through the federal Pharmacy Partnership for Long-term Care Program. ¶¶ ACIP’s ethical principles for allocating initial supplies of COVID-19 vaccine, namely to maximize benefits and minimize harms, promote justice, and mitigate health inequities ( 7 ), support the early vaccination of health care personnel and LTCF residents. Approximately 21 million U.S. health care personnel work in settings such as hospitals, LTCFs, outpatient clinics, home health care, public health clinical services, emergency medical services, and pharmacies. Health care personnel comprise clinical staff members, including nursing or medical assistants and support staff members (e.g., those who work in food, environmental, and administrative services) ( 8 ). Jurisdictions might consider first offering vaccine to health care personnel whose duties require proximity (within 6 feet) to other persons. If vaccine supply remains constrained, additional factors might be considered for subprioritization.*** Public health authorities and health care systems should work together to ensure COVID-19 vaccine access to health care personnel who are not affiliated with hospitals. Approximately 3 million adults reside in LTCFs, which include skilled nursing facilities, nursing homes, and assisted living facilities. Depending upon the number of initial vaccine doses available, jurisdictions might consider first offering vaccination to residents and health care personnel in skilled nursing facilities because of high medical acuity and COVID-19–associated mortality ( 6 ) among residents in these settings. Monitoring vaccine safety in all populations receiving COVID-19 vaccine is required under an Emergency Use Authorization. Vaccines are being studied in older adults with underlying health conditions; however, LTCF residents have not been specifically studied. ACIP members called for additional active safety monitoring in LTCFs to ensure timely reporting and evaluation of adverse events after immunization. ACIP will consider vaccine-specific recommendations and additional populations for vaccine allocation beyond Phase 1a when an FDA-authorized vaccine is available. Summary What is already known about this topic? Demand is expected to exceed supply during the first months of the national COVID-19 vaccination program. What is added by this report? The Advisory Committee on Immunization Practices (ACIP) recommended, as interim guidance, that both 1) health care personnel and 2) residents of long-term care facilities be offered COVID-19 vaccine in the initial phase of the vaccination program. What are the implications for public health practice? Federal, state, and local jurisdictions should use this guidance for COVID-19 vaccination program planning and implementation. ACIP will consider vaccine-specific recommendations and additional populations when a Food and Drug Administration–authorized vaccine is available.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                12 February 2021
                12 February 2021
                : 70
                : 6
                : 217-222
                Affiliations
                National Center for Immunization and Respiratory Diseases, CDC; Leidos, Inc., Atlanta, Georgia; Center for Global Health, CDC.
                Author notes
                Corresponding author: Kimberly Nguyen, uxp1@ 123456cdc.gov .
                Article
                mm7006e3
                10.15585/mmwr.mm7006e3
                7877585
                33571174
                e48699fc-c51d-481e-9cbd-ce7f5599d44b

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article